ReportWire

Tag: RYZB

  • Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion

    Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion

    [ad_1]

    Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash.

    Continue reading this article with a Barron’s subscription.

    View Options
    [ad_2]
    Source link

  • RYZB Stock Price | RayzeBio Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch

    RYZB Stock Price | RayzeBio Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch

    [ad_1]

    RayzeBio Inc.

    RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative robust pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225.

    [ad_2]

    Tomi Kilgore

    Source link

  • RYZB Stock Price | RayzeBio Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch

    RYZB Stock Price | RayzeBio Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch

    [ad_1]


    Intraday Data provided by FACTSET and subject to terms of use.
    Historical and current end-of-day data provided by FACTSET.
    All quotes are in local exchange time.
    Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
    Intraday data delayed at least 15 minutes or per exchange requirements.

    [ad_2]

    Source link